WaferGen Biosystems this week reported a nearly 10-fold year-over-year decline in second-quarter revenues due to an "absence of sales" of its SmartChip real-time PCR platform.

For the three months ended June 30, WaferGen logged revenues of just under $45,000 compared to around $432,000 in Q2 2010. The company also cited a decrease in sales of its SmartChip assay panels and fee-based profiling services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.